Barry Sundland, MD
Family Medicine · Aurora, CONPI 1164599585
Payments from drug & device makers
Across 108 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$547
- Amgen$300
- Merck$213
- Johnson & Johnson$178
- Boehringer Ingelheim$115
- GSK$112
- plus $832 from 16 others
What the payments were for
- Food & beverage$2,297100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $547 |
| Amgen(2 entities) | 5 | $300 |
| Merck | 8 | $213 |
| Johnson & Johnson | 10 | $178 |
| Boehringer Ingelheim | 6 | $115 |
| GSK | 6 | $112 |
| Eisai Inc. | 1 | $111 |
| Novo Nordisk | 6 | $110 |
| Pfizer | 6 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $104 |
| AstraZeneca | 6 | $84 |
| Lilly USA, LLC | 5 | $74 |
| Novartis | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Seqirus USA Inc | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Astellas Pharma US Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$244
- STEGLATRO$117
- Dayvigo$111
- DIABETES - DISEASE$104
How this compares
$2,297 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 98 | $124,277 |
| TrulicityDulaglutide | 34 | $67,655 |
| EliquisApixaban | 47 | $60,499 |
| MounjaroTirzepatide | 31 | $52,620 |
| XareltoRivaroxaban | 46 | $49,869 |
| JanuviaSitagliptin Phosphate | 36 | $46,755 |
| FarxigaDapagliflozin Propanediol | 24 | $35,220 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $32,068 |
| OzempicSemaglutide | 15 | $22,794 |
| MyrbetriqMirabegron | 22 | $22,215 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $21,197 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $20,563 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $13,222 |
| OxycontinOxycodone Hcl | 19 | $9,698 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $7,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $115 | $124,27798 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $74 | $120,27565 claims |
| MerckJanuvia, Janumet, Belsomra | $213 | $74,99866 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $112 | $65,85368 claims |
| PfizerEliquis | $107 | $60,49947 claims |
| Johnson & JohnsonXarelto | $178 | $49,86946 claims |
| AstraZenecaFarxiga, Symbicort | $84 | $42,69246 claims |
| Novo NordiskOzempic | $110 | $22,79415 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $22,21522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Aurora
- Timothy ColanderAurora$3.1M
- Matthew LewisAurora$960K
- Tamara OserAurora$288K
- Sean OserAurora$248K
- Sarah DavisAurora$26K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Mia ScottDenver$993K
- Ethan LazarusDenver$688K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.